I’ve been explaining coronary artery disease to patients for more than thirty years. This fall, I had to explain it to myself.
My calcium score came back at 51, the kind of number that earns a shrug. Then the CT angiogram showed significant disease in my distal left anterior descending and circumflex arteries, with surprisingly clean proximal vessels. Not the abstraction I’ve been discussing with patients for decades. Mine, in grayscale, on a screen.
And I caught myself asking the same question my patients ask me: If I have a significant blockage, will a stent help me live longer? For most people with stable coronary disease, the honest answer is that we have no convincing evidence it will. What’s strange is how long we’ve known that.
COURAGE told us in 2007. ISCHEMIA told us again in 2020. And this month, ISCHEMIA-EXTEND told us a third time, now with close to a decade of follow-up.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The investigators followed 5,179 patients with stable coronary disease, many with moderate or severe ischemia, who had been randomized to either an initial invasive strategy or a conservative one built on medications and lifestyle. Importantly, ISCHEMIA compared initial treatment strategies, not simply stents versus no stents; the invasive approach could include either coronary stenting or bypass surgery. After a median of 9 years, estimated 11-year mortality was 25.8 percent in the invasive group and 26.9 percent in the conservative group. The adjusted hazard ratio was 0.97, with a confidence interval wide enough to hold both benefit and harm.
Statistically, that’s a tie. If you insist on turning a one-point difference that isn’t significant into a number needed to treat (NNT), you get something around 100. I’d ask you not to. The trial didn’t show a survival benefit, and an NNT dressed up on a null result is how medical myths get started.
What stents do well is relieve angina, and I don’t want to undersell that. If a patient can’t walk to the mailbox without chest pressure, restoring blood flow can give them a big piece of their life back. Relieving suffering is a perfectly good reason to do a procedure. It’s just a different promise from keeping someone alive, and we blur the two far too often.
To be clear, none of this applies to someone in the middle of a heart attack, where emergency intervention saves lives. Nor should anyone stretch these results to cover significant left main disease, severely impaired ventricular function, or angina that’s intolerable despite medication; those patients weren’t well represented in ISCHEMIA. But for the enormous population of people with stable disease, the evidence hasn’t budged in nearly twenty years.
So why do we keep treating every visible narrowing as a problem that has to be fixed?
Part of it, I think, is that the cath lab puts on a great show. There’s the tight lesion. There’s the balloon. There’s the stent, and moments later there’s a wide-open artery. Those before-and-after pictures are hard to argue with. What they can’t show you is whether the patient will live one day longer.
We’ve also spent generations teaching patients that arteries clog like kitchen drains until nothing gets through. It’s a tidy story, and it’s mostly wrong. Heart attacks often happen when a plaque ruptures or erodes and a clot forms on top of it, and the culprit plaque frequently wasn’t causing a severe narrowing beforehand. Opening the one stenosis that looks scary on film does nothing about the biology at work in the rest of the coronary tree. That’s why systemic prevention matters, and why a successful procedure isn’t the same thing as a successful strategy.
I like to call myself a lipidologist in recovery. I’ve spent a good part of my career studying cholesterol and poking at the conventional wisdom on atherosclerosis, so I’ll admit there’s some irony in landing on this side of it. The diagnosis hasn’t cured me of skepticism. If anything, it’s sharpened the questions I care about: What’s my actual risk? Which treatments meaningfully lower it? How big is the absolute benefit? And what do I give up to get it?
I’m not anti-stent. I’m against pretending stents do something that randomized trials have repeatedly failed to show in stable disease. A stent that relieves disabling angina is doing exactly what it should. A stent placed mainly to help an asymptomatic patient live longer deserves a much harder conversation.
I’ve had versions of that conversation with patients for years. It turns out it feels different from the other side of the exam table. Explaining the evidence is one thing. Looking at your own arteries and deciding to trust it is another.
If ISCHEMIA-EXTEND gives us anything, it’s permission to finally say something simple to our patients and mean it: A stent can often make your chest pain better. But if your disease is stable, don’t assume it will help you live longer.
Those are different outcomes, and our patients deserve to know which one they’re signing up for.
Larry Kaskel is an internist and self-described “lipidologist in recovery” who has practiced medicine for more than 35 years, with an emphasis on prevention, wellness, and longevity. He runs a concierge medical practice in the Chicago area and serves on the teaching faculty at Northwestern University Feinberg School of Medicine.
He is the former host of Lipid Luminations on ReachMD and author of Dr. Kaskel’s Living in Wellness. His writing frequently challenges conventional medical wisdom and explores new approaches to preventing chronic disease.
Dr. Kaskel is also the founder and CEO of Holy Chiat, a fiber supplement.
Your KevinMD author page is one of the top results for your name. Turn it into a premium profile, publish in 1 to 3 days, and get a guaranteed podcast slot.
